Nasdaq nmra.

Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. The stock is expected to list on the Nasdaq under the ticker symbol “NMRA.” J.P. Morgan, BofA Securities, Guggenheim Securities, RBC Capital Markets and William Blair are the underwriters. The ...2 days ago · View Neumora Therapeutics, Inc NMRA investment & stock information. Get the latest Neumora Therapeutics, Inc NMRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. WATERTOWN, Mass., Oct. 30, 2023 -- Neumora Therapeutics, Inc. , a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will...

The latest Neumora Therapeutics stock prices, stock quotes, news, and NMRA history to help you invest and trade smarter. ... (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company ...

Minim, Inc. (NASDAQ: MINM) gained 29.3% to $1.19 in pre-market trading after gaining over 13% on Wednesday. ... (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics ...Sep 12, 2023 · A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. ( NASDAQ: NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended ...

Nov 23, 2023 · On Wednesday, Neumora Therapeutics Inc. [NASDAQ: NMRA] rose 1.88% to $11.91. The stock’s lowest price that day was $11.76, but it reached a high of $12.14 in the same session. During the last five days, there has been a drop of approximately -0.83%. Over the course of the year, Neumora Therapeutics Inc. shares have dropped approximately -26.71%. Within the last quarter, Neumora Therapeutics (NASDAQ:NMRA) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, Neumora ...WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience …The latest Neumora Therapeutics stock prices, stock quotes, news, and NMRA history to help you invest and trade smarter. ... (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company ...

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last issued its earnings results on Wednesday, November 1st. The company reported ($1.14) earnings per share for the quarter, missing the ...

Nov 27, 2023 · 1.55. EBIT. -130.9. -237.31. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for Neumora Therapeutics, Inc. (NMRA). See many years of revenue, expenses and ...

Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...Nov 8, 2023 · Within the last quarter, Neumora Therapeutics (NASDAQ:NMRA) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, Neumora ... NMRA Neumora Therapeutics, Inc. Stock Price & Overview. Follow 212 followers. $12.250.00 (0.00%)11:37 AM 12/01/23. NASDAQ | $USD | Realtime. Summary · Ratings ...WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November: Guggenheim Healthcare Talks 5th Annual INI …View live price data for NMRA (Neumora Therapeutics, Inc.) on TrendSpider to track real-time price action, options flow, and news on this asset and hundreds more. Dark Light. Search Ctrl + K. Login Try full version. Smart Watchlists. NMRA. NMRA. Neumora Therapeutics, Inc. 10.02 USD +0.38 (+3.94%) Last updated Oct 13, 21:00 UTC. …Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...Atomera Inc (NASDAQ:ATOM)’s traded shares stood at 0.16 million during the last session, with the company’s beta value hitting 1.45. At the close of trading, the stock’s price was $6.97, to imply an increase of 0.29% or $0.02 in intraday trading. The ATOM share’s 52-week high remains $10.72 ...

Dec 2, 2023 · Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) – Investment analysts at William Blair decreased their FY2023 earnings estimates for Neumora Therapeutics in a report issued on Monday, November 27th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($4.25) per share for the year, down from their previous estimate of […] NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The ...Nov 27, 2023 · NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ... 14 Sep 2023 ... Home · News; NMRA. Neumora Therapeutics Inc. - NMRA STOCK NEWS. IMPACT. SENTIMENT. 11/27/2023 07:00 AM. NMRA : Nasdaq.Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.Oct 10, 2023 · WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug ...

Common Stock stock price (NMRA). NASDAQ: NMRA. Buying or selling a stock that's not traded in your local currency? Don't let the currency conversion trip you ...

According to the issued ratings of 6 analysts in the last year, the consensus rating for Neumora Therapeutics stock is Buy based on the current 6 buy ratings for NMRA. The average twelve-month price prediction for Neumora Therapeutics is $22.67 with a high price target of $26.00 and a low price target of $18.00.Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update.NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ...The Watertown, MA-based Neumora Therapeutics ( NASDAQ: NMRA ), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its ...For Neumora Therapeutics Inc (NASDAQ:NMRA), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $17.74 and a 52-week-low of $9.90.NMRA Most Active Options. Most Active LEAPS Data is currently not available. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...

Neumora Therapeutics, Inc. Common Stock (NMRA) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for ...

NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders.

NMRA-140 protected WM performance from the detrimental effects of FG7142-induced stress and exhibited no significant effect under non-stress conditions. Collectively, these data highlight the functional influence of the KOR system in mediating stress-induced dysfunction of executive processes and suggest that modulating KOR …(NASDAQ: NMRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.21%. What is NMRA's Price Target? According to 5 Wall Street analyst s that have issued a 1 year NMRA price target, the average NMRA price target is $22.00 , with the highest NMRA stock price forecast at $26.00 and the lowest NMRA stock ... Find the latest Earnings Report Date for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.Oct 18, 2023 · Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ... Get the latest Neumora Therapeutics, Inc NMRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 minutes delayed.Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.Encontre o valor de abertura e fechamento das cotações NMRA para ficar atualizado sobre as tendências do mercado financeiro. Compartilhe sua visão de mercado, interaja com …Nov 1, 2023 · Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...

See the latest Neumora Therapeutics Inc stock price (NMRA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...Based on analysts offering 12 month price targets for NMRA in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .On Wednesday, Neumora Therapeutics Inc. [NASDAQ: NMRA] rose 1.88% to $11.91. The stock’s lowest price that day was $11.76, but it reached a high of $12.14 in the same session. During the last five days, there has been a drop of approximately -0.83%. Over the course of the year, Neumora Therapeutics Inc. shares have dropped approximately -26.71%.Instagram:https://instagram. portfolio stock trackermobile bank with virtual debit cardseimogoldman sachs card Research Neumora Therapeutics' (Nasdaq:NMRA) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, ... It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; ... nasdaq kfrcbest broker for shorting hard to borrow stocks Nov 22, 2023 · Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). asus flow x13 2023 Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for ...Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the ...On Wednesday, Neumora Therapeutics Inc. [NASDAQ: NMRA] rose 1.88% to $11.91. The stock’s lowest price that day was $11.76, but it reached a high of $12.14 in the same session. During the last five days, there has been a drop of approximately -0.83%. Over the course of the year, Neumora Therapeutics Inc. shares have dropped …